• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to Its Board of Directors

    12/2/20 1:00:00 AM ET
    $LLY
    $JNJ
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email

    LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately.

    “I am very pleased to welcome Jennifer, David, and Renée, three extremely accomplished executives with extensive biopharmaceutical backgrounds, to our board of directors,” said Khurem Farooq, Chief Executive Officer. “We look forward to their valuable contributions and unique perspectives as we continue our work to develop gene therapy beyond rare disease with the goal of delivering new medicines to people with retinal diseases.”

    Ms. Cook was most recently the Chief Executive Officer of GRAIL, a healthcare company focused on the early detection of cancer. Prior to joining GRAIL, she held a number of leadership positions during her 25-year tenure with Roche/Genentech, including leading Roche Pharmaceuticals’ European commercial business, Global Clinical Operations, U.S. and Global Product Portfolio Management, the U.S. Immunology and Ophthalmology Business Unit and Market Development. She currently serves on the boards of directors of Denali Therapeutics, BridgeBio Pharma and Ambys Medicines. Ms. Cook holds a B.A. in human biology and an M.S. in biology from Stanford University, as well as an MBA from the Haas School of Business at the University of California, Berkeley.

    Mr. Fellows was most recently the Chief Executive Officer of Nightstar Therapeutics, a retinal gene therapy company acquired by Biogen in 2019. Prior to joining Nightstar, he was the Vice President of Johnson & Johnson’s Vision Care Franchise where he led the global marketing, new product and licensing activities. Before joining Johnson & Johnson, Mr. Fellows held leadership positions at Allergan, Inc., for 25 years where he served primarily in sales and marketing in a number of capacities, including Regional President, Corporate Vice President, and Senior Vice President across North America, Europe and Asia. He currently serves as the chairman of the board for Oxular Limited and is a board member of the Glaucoma Foundation. Mr. Fellows holds a B.A. in psychology from Butler University.

    Ms. Galá currently serves as the Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals, a global biopharmaceutical company. Prior to joining Jazz, she served as the Chief Financial Officer of GRAIL. Before joining GRAIL, Ms. Galá served as the Senior Vice President and Chief Financial Officer of Theravance Biopharma, where she led the company’s spin-out transaction from Innoviva, Inc. Ms. Galá has also served in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company. Prior to joining Eli Lilly, she spent seven years in the energy industry in positions focused on corporate finance, project finance and mergers and acquisitions. She currently serves on the board of directors of Gossamer Bio where she chairs its audit committee. Ms. Galá holds a B.S. in mathematics from Vanderbilt University and an MBA from Columbia Business School.

    About Gyroscope: Vision for Life

    Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (AMD). Our lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.

    Syncona Ltd, our lead investor, helped us create a leading retinal gene therapy company combining discovery, research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness. For more information visit: www.gyroscopetx.com and follow us on Twitter (@GyroscopeTx) and on LinkedIn.

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY
    $JNJ
    $INVA

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Eli Lilly and Company
    $LLY
    9/17/2025$830.00Buy → Hold
    Berenberg
    Eli Lilly and Company
    $LLY
    8/27/2025$700.00Reduce → Hold
    HSBC Securities
    Eli Lilly and Company
    $LLY
    8/18/2025$700.00Outperform → Neutral
    Daiwa Securities
    Innoviva Inc.
    $INVA
    8/11/2025$45.00Outperform
    Oppenheimer
    Eli Lilly and Company
    $LLY
    8/7/2025$715.00Outperform → Market Perform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Innoviva Inc.
    $INVA
    7/14/2025$40.00Buy
    H.C. Wainwright
    More analyst ratings

    $LLY
    $JNJ
    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly downgraded by Berenberg with a new price target

    Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00

    9/17/25 7:55:15 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Eli Lilly from Reduce to Hold and set a new price target of $700.00

    8/27/25 8:16:34 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    9/8/25 7:55:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.

    SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)

    9/3/25 3:23:16 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lilly Endowment Inc sold $18,058,643 worth of shares (23,665 units at $763.10), decreasing direct ownership by 0.02% to 95,606,687 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    9/22/25 4:00:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lilly Endowment Inc sold $81,531,959 worth of shares (106,626 units at $764.65), decreasing direct ownership by 0.11% to 95,630,352 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    9/19/25 4:00:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sulzberger Gabrielle was granted 7 shares, increasing direct ownership by 0.24% to 2,722 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    9/17/25 4:49:54 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

    TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg  Approval was based on PROTOSTAR study, which showed pediatric patients receiving TREMFYA® achieved high levels of skin clearance vs. placebo at Week 16 HORSHAM, Pa., Sept. 29, 2025 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), w

    9/29/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

    New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines  Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs INDIANAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to support early-stage biotechnology companies by providing lab space and opportunities to collaborate with Lilly scientists. The new facility, developed by and operated in partnership with Alexandria Real Estate Equities, Inc., is

    9/26/25 8:30:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

    Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. "Kisunla demonst

    9/25/25 6:39:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anne White to Retire as Executive Vice President and President, Lilly Neuroscience

    INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh

    8/20/25 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports second-quarter 2025 financial results and raises guidance

    Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi

    8/7/25 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

    Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,

    8/6/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    $JNJ
    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Innoviva Inc.

    SC 13G - Innoviva, Inc. (0001080014) (Subject)

    5/13/24 1:58:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care